Lv11
20 积分 2024-01-04 加入
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
3小时前
已完结
Developments of MEK inhibitors as future cancer therapies: what have we learned from preclinical and clinical studies?
4天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
1个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
2个月前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
2个月前
已完结
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
2个月前
已完结
Chronic lymphocytic leukaemia
2个月前
已完结
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
2个月前
已完结
Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG‐96/02 study
3个月前
已完结
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study
3个月前
已完结
皖公网安备34019202002308
